Zolpimist is a drug owned by Aytu Bioscience Inc. It is protected by 2 US drug patents filed from 2013 to 2016. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 07, 2032. Details of Zolpimist's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US8236285 | Buccal, polar and non-polar spray containing zolpidem |
Aug, 2032
(8 years from now) | Active |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7632517 | Buccal, polar and non-polar spray containing zolpidem |
Oct, 2017
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zolpimist's patents.
Latest Legal Activities on Zolpimist's Patents
Given below is the list of recent legal activities going on the following patents of Zolpimist.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Expire Patent | 15 Jan, 2018 | US7632517 |
| Expire Patent | 02 Sep, 2016 | US8236285 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 09 Apr, 2014 | US7632517 |
| Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted | 09 Apr, 2014 | US7632517 |
| Petition Decision - Accept Late Payment of Maintenance Fees - Granted | 09 Apr, 2014 | US7632517 |
| Petition to Accept Late Payment of Maintenance Fee Payment Filed | 09 Apr, 2014 | US7632517 |
| Expire Patent | 10 Jan, 2014 | US7632517 |
| Patent Issue Date Used in PTA Calculation | 07 Aug, 2012 | US8236285 |
| Recordation of Patent Grant Mailed | 07 Aug, 2012 | US8236285 |
| Issue Notification Mailed | 18 Jul, 2012 | US8236285 |
US patents provide insights into the exclusivity only within the United States, but Zolpimist is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zolpimist's family patents as well as insights into ongoing legal events on those patents.
Zolpimist's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Zolpimist's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 07, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zolpimist Generics:
Zolpidem Tartrate is the generic name for the brand Zolpimist. 30 different companies have already filed for the generic of Zolpimist, with Endo Operations having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zolpimist's generic
About Zolpimist
Zolpimist is a drug owned by Aytu Bioscience Inc. It is used for treating symptoms of transient insomnia. Zolpimist uses Zolpidem Tartrate as an active ingredient. Zolpimist was launched by Aytu in 2008.
Market Authorisation Date:
Zolpimist was approved by FDA for market use on 19 December, 2008.
Active Ingredient:
Zolpimist uses Zolpidem Tartrate as the active ingredient. Check out other Drugs and Companies using Zolpidem Tartrate ingredient
Treatment:
Zolpimist is used for treating symptoms of transient insomnia.
Dosage:
Zolpimist is available in spray, metered form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/SPRAY | SPRAY, METERED | Discontinued | ORAL |